United Therapeutics Corp (UTHR) valuation against sector peers: P/E 19.4 (sector median 29.2), P/B 3.8, free-cash-flow yield 3.6%, P/S 7.5.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Metric	UTHR	Sector median	vs median
P/E	19.4	29.2 · n=157	33% below
P/B	3.8	3.8 · n=307	near the median
P/S	7.5	4.1 · n=300	84% above
EV/EBIT	—	25.6 · n=145	—
Free-cash-flow yield	3.6%	1.5% · n=289	145% above
Dividend yield	0.00%	0.00% · n=362	—
Return on equity	19.1%	−2.4% · n=306	—
Return on invested capital	—	0.6% · n=280	—
Gross margin	86.3%	63.3% · n=205	36% above
Net debt / EBITDA	—	1.30 · n=150	—

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.

Sector peers

The largest companies of the same sector and region.

Instrument	P/E	P/B	EV/EBIT	Free-cash-flow yield	Dividend yield	Smart Score
LLYEli Lilly & Co	46.2	31.6	—	1.5%	0.6%	6/10
JNJJohnson & Johnson	41.3	8.2	—	3.1%	1.9%	8/10
ABBVAbbVie	50.0	—	27.6	3.7%	2.9%	6/10
MRKMerck	147.5	8.1	—	4.1%	2.3%	8/10
UNHUnitedHealth	22.2	3.4	16.9	6.5%	2.3%	10/10
TMOThermo Fisher Scientific	36.4	4.7	34.5	3.0%	0.3%	9/10
AMGNAmgen	26.5	17.4	23.0	3.8%	2.2%	8/10
GILDGilead Sciences	—	15.9	—	6.7%	1.9%	4/10
ABTAbbott	40.5	3.7	32.8	3.5%	2.8%	6/10
PFEPfizer	41.5	1.9	—	7.0%	7.3%	1/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 04 Nov 2026

Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.

Cookie settings